Atherosclerosis and obesity share pathological features including inflammation mediated by innate and adaptive immune cells. LXRa, a nuclear receptor, plays a central role in the transcription of inflammatory and lipid metabolic genes. LXRa is modulated by phosphorylation at serine 196 (LXRa pS196), however, the functional consequences of LXRa pS196 in hematopoietic cell precursors in atherosclerosis and obesity have not been investigated. To assess the importance of LXRa phosphorylation, bone marrow from LXRaWT and S196A mice was transplanted into Ldlr -/mice, which were fed a high fat, high cholesterol diet prior to evaluation
of atherosclerosis and obesity. Plaques from S196A mice showed reduced inflammatory monocyte recruitment, lipid accumulation, and macrophage proliferation. Expression profiling of CD68+ cells from S196A mouse plaques revealed downregulation of pro-inflammatory genes and upregulation of mitochondrial genes characteristic of anti-inflammatory macrophages. Furthermore, S196A mice had lower body weight and less visceral adipose tissue;
this was associated with transcriptional reprograming of the adipose tissue macrophages and resolution of inflammation resulting in less fat accumulation within adipocytes. Thus, reducing LXRa pS196 in hematopoietic cells attenuates atherosclerosis and obesity by reprogramming the transcriptional activity of LXRa to an anti-inflammatory phenotype.
INTRODUCTION
LXRa is a desmosterol-and oxysterol-activated transcription factor that controls the expression of genes involved in cholesterol homeostasis, apoptosis, inflammation, and cell movement (1, 2) . Activation of LXRa inhibits atherosclerosis progression in mouse models, which depends in part on LXRa activity in macrophages (3, 4) . During atherogenesis, immune cellsmostly cholesterol-loaded macrophages accumulate in the arterial wall and form plaques (5) (6) (7) (8) (9) .
Obesity, like atherosclerosis, is associated with lipid accumulation and chronic inflammation (10) .
Macrophages accumulate in the visceral adipose tissue (VAT) of animals after being fed a high fat diet (11, 12) , and produce inflammatory cytokines that contribute to metabolic dysfunction (13) .
We and others have shown that LXRa's ability to activate transcription is modulated by phosphorylation at serine 196 (S196 in mouse LXRa and S198 in human LXRa), which significantly modifies its target gene repertoire (14) (15) (16) (17) . Whereas LXRa pS196 promotes an inflammatory gene signature, unphosphorylated LXRa stimulates an anti-inflammatory gene expression profile. Consistent with this idea, in mouse models we observed an increase in LXRa pS196 in plaque macrophages under inflammatory conditions associated with atherosclerosis progression, and a decrease in LXRa pS196 during the resolution of inflammation in regressing plaques (16, 18) . Cholesterol loaded macrophages and hepatocytes also showed increased LXRa pS196 (15, 19) . Thus, the lack of LXRa phosphorylation at S196 appears associated with an antiinflammatory phenotype.
In this study, we examined the impact of LXRa pS196 in immune cells on atherosclerosis progression and obesity, using a bone marrow transplant approach from wild type (WT) and LXRa S196A knock-in mice, which are unable to be phosphorylated and should retain only the antiinflammatory actions of LXRa. This approach has the potential to uncover the importance of LXRa phosphorylation activities within immune cells, while avoiding confounding effects of LXRa S196A expression in other organs. This strategy can also provide insight into potential communication between immune cell types when contrasted with effects on atherosclerosis and obesity from, for example, myeloid-specific LXRa S196A expression. Characterizing the role of LXRa pS196 in myeloid cells and their contribution to atherosclerosis and obesity has the potential to reveal new therapeutic strategies for both pathologies.
RESULTS

LXRa S196A promotes an atheroprotective lipoprotein phenotype in a bone marrow transplant model in Ldlr -/mice
Given the role that LXRa plays in cholesterol homeostasis and control of inflammation, we hypothesized that reducing LXRa pS196 would decrease inflammation and reduce atherosclerosis progression. Thus, we used a LXRa phosphorylation-deficient knock-in mouse, LXRa S196A, in a bone marrow transplantation model (14) . This approach allowed us to interrogate the requirement of LXRa phosphorylation on the entire cadre of immune cells expressing S196A compared to wild type (WT). LXRa S196A or wild type (WT) mice were used as donors for bone marrow transplant into Ldlr -/recipients. Following reconstitution, mice were fed a western diet (42% kcal fat and 0.3% kcal cholesterol) for 16 weeks after which time atherogenesis was assessed ( Fig. 1A) . LXRa S196A did not alter the levels of total cholesterol ( Fig. 1B) . After lipoprotein separation by fast protein liquid chromatography (FPLC), S196A mice showed decreased atherogenic IDL/LDL cholesterol (LDL-C) (20) and increased atheroprotective HDL cholesterol (HDL-C) compared to controls (Fig. 1C ). We confirmed this increase by directly measuring HDL-C concentration in the plasma (Fig. S1A ). Non-esterified fatty acid (NEFA) and triglyceride (TG) levels in plasma were not changed by LXRa S196A (Figs. 1D and E). Thus, LXRa S196A mice exhibit an atheroprotective lipoprotein profile with high HDL-C and low LDL-C.
LXRa S196A expressed in bone marrow-derived cells affects multiple kinetic factors governing plaque macrophage content
The favorable lipoprotein profile exhibited by the LXRa S196A mice might lead to reduced lipid accumulation within cells of the atherosclerotic plaque. Consistent with this, we found a ~40 % reduction in the neutral lipid content within the LXRa S196A compared to WT plaque as measured by Oil Red O staining (Figs. 2A and S1B). We also measured plaque area and total macrophage content by CD68 staining. We observed trends towards a reduction in total plaque area ( Fig. S1C ) and CD68+ cell area (Figs. 2B and S1D), whereas necrotic area was unchanged ( Fig. 2C ). Since plaque macrophage content reflects multiple kinetic factors including monocyte recruitment, macrophage proliferation and apoptosis, we also measured each of these parameters. To determine the Ly6C high monocytes (precursors of pro-inflammatory M1 macrophages in progressing plaques) and Ly6C low monocytes (potential precursors of antiinflammatory M2 macrophages) content, mice were injected with EdU (5-ethynyl-2'deoxyuridine) and fluorescent latex beads, 3 days or 1 day before harvest, respectively (21) . EdU is incorporated into the DNA of proliferating Ly6C high monocytes while fluorescent beads are engulfed by Ly6C low monocytes. Quantification of EdU-or bead-labeled monocytes infiltrating into the plaques revealed a significant decrease (~50%) in the recruitment of inflammation-prone Ly6C high monocytes into the plaques of LXRa S196A relative to LXRa WT mice ( Fig. 2D ), despite no changes in circulating monocyte number (Figs. S2A-D). In contrast, we did not observe a change in the recruitment of Ly6C low monocytes into the plaque between LXRa S196A and WT mice ( Fig.2E ). Smooth muscle cells in the plaque under high cholesterol can transdifferentiate into macrophage-like CD68+ cells (22) , and potentially contribute to the CD68 content. Therefore, we measured the number of cells expressing alpha smooth muscle actin (SMaA), a marker of smooth muscle cells in LXRa S196A and WT plaques and no significant difference was observed ( Fig.   S1E ).
We did observe a ~40% decrease in macrophage proliferation within the plaque in LXRa S196A relative to WT by co-staining with the proliferation marker Ki67 and the macrophage marker CD68 (Fig. 2F) . Similarly, we observed a ~40% reduction in apoptosis in LXRa S196A compared to WT as measured by cleaved-caspase 3 and CD68 co-staining ( Fig. 2G ), and would result in macrophage accumulation in the plaque. This could explain why we do not observe a significant reduction in macrophage content in the plaque despite a decrease in both, Ly6C-high monocyte recruitment and macrophage proliferation in S196A plaques. These striking kinetic differences in plaque characteristics between the S196A and WT in the bone marrow transplant model suggests that expression of S196A within myeloid cells is reducing macrophage proliferation, decreasing macrophage recruitment and apoptosis within the plaque microenvironment.
LXRa S196A promotes expression of genes regulating mitochondrial activity and decreases inflammatory pathways in the plaque
To further elucidate the mechanisms governing macrophage inflammatory response in atherosclerosis, we examined gene expression changes from LXRa WT and LXRa S196A plaque CD68+ cells collected by laser-capture microdissection (23) . RNA sequencing (RNA-seq) analysis revealed significant changes in the expression of multiple transcripts. We found that LXRa S196A 6 induced 701 and repressed 346 genes in plaque CD68+ cells compared to LXRa WT (Fold change > 1.5, p-value < 0.05) (Figs. 3A, S3 and TableS1). Ingenuity Pathway Analysis (IPA) (24) of the genes upregulated by LXRa S196A identified mitochondrial function and oxidative phosphorylation (Oxphos) as the top enriched pathways, followed by sirtuin signaling, the TCA cycle and fatty acid oxidation. This suggests that mitochondrial activity and energy metabolism, characteristics of metabolic pathways upregulated in anti-inflammatory macrophages, are induced within the LXRa S196A CD68+ cells relative to WT ( Fig. 3B -C) (25, 26) . Genes downregulated by S196A were associated with inflammatory pathways including phagocytosis in macrophages, nuclear factor of activated T cells (NFAT), Th2 and NFκB signaling ( Fig. 3B ). Transcription factor analysis via IPA revealed that the majority of the genes upregulated in LXRa S196A compared to WT CD68+ cells are associated with PGC1α (PPARGC1A), and to lesser extent by TP53, ESRRα, NUR77 (NR4A1) and mineralocorticoid receptor (NR3C2) ( Fig. 3D ). In support of skewing macrophages to an anti-inflammatory phenotype, PGC1a is a co-activator of LXRa (27) and a regulator of mitochondrial biogenesis and function (28, 29) . PGC1a is activated by deacetylation through sirtuins (30) , and this may be strengthened through increased sirtuin signaling identified by IAP in LXRa S196A. Additionally, ESRRα is required for mitochondrial biogenesis and activation of mitochondrial genes (31) . NUR77 and TP53 control cell cycle and cell death processes (32, 33) . This is consistent with decreased proliferation and apoptosis of macrophages in the plaques expressing LXRa S196A. Genes downregulated by LXRa S196A compared to WT are enriched for members of the signal transducer and activator of transcription family (STAT6, STAT1, STAT3), known to regulate gene expression ( Fig. 3D ) (34) (35) (36) (37) . Thus, CD68+ cells within the plaque expressing LXRa S196A exhibited an increase in the expression of genes involved in mitochondrial metabolic activity and decreased in genes associated with inflammation, consistent with a more anti-inflammatory macrophage phenotype.
LXRa S196A increases mitochondrial respiration, ATP production and mitochondrial biogenesis in M1 and M2 BMDMs
Given the relationship of LXRa S196A to altered expression of genes in plaque CD68+ cells involved in mitochondrial oxidative phosphorylation, we assesses whether LXRa S196A enhanced mitochondrial respiration. In bone marrow derived macrophages (BMDM) derived from LXRa WT and LXRa S196A, we determined the effect of LXRa phosphorylation on 7 mitochondrial function by Seahorse XF Extracellular Flux analysis of the oxygen consumption rate (OCR) in BMDM under pro-and anti-inflammatory conditions. In M1 and M2 BMDMs LXRa S196A showed higher basal respiration, ATP production and maximal respiration rate compared to control cells ( Fig. 4A ), suggesting that reduction of LXRa phosphorylation promotes electron transport chain capacity in the mitochondria.
One possibility for this could be by increasing mitochondria biogenesis in LXRa S196A cells. To examine this, we quantified mitochondrial abundance in LXRa WT and S196A BMDMs by labeling the mitochondria within live cells using the mitochondrial-specific probe, MitoTracker (38) . Consistent with the enhanced mitochondrial activity in LXRa S196A, we found increased MitoTracker positive cells and an increase in mitochondrial (mt) DNA in M1 and M2 LXRa S196A cells compared to LXRa WT ( Fig. 4B -C).
Since LXRa S196A gene expression in plaque CD68+ cells converge on the mitochondrion, we evaluated mitochondrial morphology, which is crucial for the maintenance of the mitochondrial membrane potential and ATP production (39) by performing transmission electron microscopy of LXRa WT and S196A M1 and M2 BMDMs ( Fig. 4D ). We observed alterations in mitochondrial morphology and ultrastructural changes in M1 LXRa WT BMDMs (less electron dense cristae) as compared with M1 LXRa S196A BMDMs (more electron dense cristae). The mitochondria observed in M1 LXRa S196A BMDMs look similar to mitochondria found in M2 BMDMs from both WT and LXRa S196A. This is consistent with the mitochondria from M1 LXRa S196A producing ATP through oxidative phosphorylation ( Fig 4A) , a mechanism that is normally found in the mitochondria of anti-inflammatory macrophages (40) . Collectively, these data demonstrate that reduction of LXRa phosphorylation drives mitochondrial respiration processes that are akin to an anti-inflammatory metabolic response likely through its modulation of multiple mitochondrial genes (Fig. 3B ), and enhanced mitochondrial biogenesis (Figs. 4B-C).
LXRa S196A protects from diet-induced obesity
Obesity and atherosclerosis share pathological features including lipid accumulation, inflammation and cytokine production mediated by both innate and adaptive immune cells that accumulate within their respective tissues (10, (41) (42) (43) . We therefore examined whether LXRa S196A affected fat deposition and immune cell recruitment in adipose tissue in the same mice as those analyzed for atherosclerosis progression.
Remarkably, LXRa S196A mice showed less weight gain during the experiment ( Fig.   S4A ). They weighed 15% less than WT mice after 16 weeks of western diet feeding ( Fig. 5A ) and had equivalent food intake during the course of the experiment (Fig. S4B ). This was observed in two independent cohorts (not shown). We confirmed that total body fat mass was lower (8.2 g vs 10.8 g) in LXRa S196A compared to control WT mice by Dual energy X-ray absorptiometry (DEXA) scanning ( Fig. 5B ). No differences were observed in bone mineral density and lean body mass between LXRa S196A and LXRa WT mice ( Fig. S4C ). LXRa S196A mice relative to WT also showed reduced VAT, in particular perigonadal white adipose tissue mass (pWAT: 1.32 g vs 1.75 g) ( Fig. 5C ). This was associated with a decrease in adipocyte size in LXRa S196A compared to WT mice (2471 vs 3570 µm 2 ) (Figs. 5D-E), consistent with less lipid accumulation. The number of macrophages determined by F4/80+ cell staining was similar in S196A compared to WT pWAT (Figs. S4D-E), although a trend toward a decrease in the number of crown-like structures, a hallmark of the pro-inflammatory processes in adipose tissue (11, 44) , was observed ( Fig. S4F ).
A possibility for the adipocyte phenotype is that the myeloid cells from the LXRa S196A signal to the adipocytes and decrease the expression of genes involved in lipid accumulation or increase the expression of genes involved in lipolysis. We therefore determined expression in adipocytes from mice reconstituted with bone marrow from either WT or S196A of Fabp4 (Fatty acid binding protein 4), which promotes fatty acid uptake, and Plin2 (Perilipin2), which coat intracellular lipid droplets to develop and maintain adipose tissue. We also examined the expression in adipocytes of lipolysis activators Atgl (Adipose triglyceride lipase) and Hsl (Hormone-sensitive lipase), which hydrolyze stored triglycerides in adipose tissue. The expression in adipocytes of none of these gene were affected in LXRa S196A compared to WT mice ( Fig.   S5A -B). We also determined the expression Adipoq (adiponectin), a hormone secreted by adipocytes (adipokine) with anti-inflammatory activities that regulate energy homeostasis, glucose and lipid metabolism. Although the expression of Adipoq mRNA did not differ significantly in the adipocytes between WT and S196A, we did find the level of adiponectin protein to be higher in the plasma of LXRa S196A compare to its wild type counterpart ( Fig. S5C ). This is consistent with the plasma levels of adiponectin being higher in lean versus obese rodent and humans (45, 46) .
Given that brown adipose tissue (BAT) has the capacity to control energy homeostasis (47), we also examined whether BAT morphology and UCP1 levels were affected in LXRa S196A 9 relative to LXRa WT mice. BAT tissue morphology and UCP1 protein abundance by immunohistochemistry (IHC) were unchanged in S196A versus WT mice on western diet ( Fig.   S5D ). This suggests that BAT function is not contributing to the lower adipose deposition observed in LXRa S196A compared to WT. Also, liver weight was reduced in LXRa S196A compared to WT ( Fig. S5B ), but hepatic lipid droplet accumulation was comparable in LXRa S196A and WT mice (Figs. S5F-G). These data demonstrate that LXRa S196A expressed in the bone marrow protects Ldlr -/mice from diet-induced obesity when challenged by a western diet.
LXRa S196A ATMs are less inflammatory
Analysis of the immune cells present in the pWAT by flow cytometry revealed LXRa S196A affects various immune cell populations ( Fig. S6A ). Adipocyte tissue macrophages (ATMs) were decreased in S196A compared to WT (Fig. 6A ). The number of pro-inflammatory FBC macrophages (M1-like: F4/80+CD11b+CD11c+) was reduced (Figs. 6B-C), while the number of anti-inflammatory FB macrophages (M2-like: F4/80+CD11b+CD11c-) was not changed (Fig. 6D ). This results in a higher ratio of inflammation resolving FB versus inflammation promoting FBC macrophages in LXRa S196A compared to LXRa WT adipose tissue ( Fig. 6E ).
Analysis of the percentage of dendritic cells (DC) and T cell populations did not demonstrate any significant changes between WT and LXRa S196A ( Fig. S6B-G) . Therefore, the LXRa S196A expressing mice resulted in fewer inflammatory ATM in pWAT, characteristic of a leaner phenotype.
To explore pathways underlying the changes observed in the ATM phenotype in LXRa S196A, FB and FBC were sorted from WT and S196A, and RNA-seq analysis was performed. We first analyzed genes in LXRa WT and LXRa S196A that were differentially expressed in FB versus FBC (Fold change > 1.5, p-value < 0.05). We then determined which genes were differentially induced or repressed between LXRa WT or LXRa S196A ( Fig. 6F and Table S2) followed by IPA ( Fig. 6 -G). Enriched pathways in genes preferentially induced by LXRa WT compared to S196A in ATMs include pro-inflammatory factors, such as IL17A and interferon, TREM1 and TLR signaling pathways. In particular, RelA (p65 subunit of NFkB) mRNA was 2.3 fold higher in WT versus S196A in ATMs (Table S3 ). Pathways associated with genes upregulated in LXRa S196A compared to WT include lysine degradation, with Aldh7a1 (Aldehyde Dehydrogenase 7 Family Member A1) upregulated 8.4 fold (Table S3 ). ALDH7A1 protects cells from oxidative stress by metabolizing lipid peroxidation-derived aldehydes (48) . Additional enriched pathways from genes preferentially induced in LXRa S196A ATMs include, sumoylation, in particular Senp7 [SUMO-specific proteases 7; upregulated 5.8-fold in S196A versus WT (Table S3 ) and involved in the deconjugation of Sumo moieties (49)], a key determinant of transrepression by LXRa (50), and chromatin pathways, which have important ties to macrophage activation in atherosclerotic plaques (51) as well as lipid metabolism and cell cycle inhibitory pathways. An increase in the cell cycle inhibitory pathway in LXRa S196A would suggest decreased macrophage proliferation. Pathways downregulated in LXRa S196A include inflammatory processes (NFAT and IL6 signaling) ( Fig. 6G and Table S3 ). Together, these data suggest that reduction of pS196 in ATMs decreases inflammatory mediated signaling to adipocytes. This could explain the decrease in lipid accumulation and in adipocyte hypertrophy in pWAT, leading to the reduction in obesity in LXRa S196A compared to WT mice.
Conditioned media from LXRa S196A BMDMs reduces lipid accumulation in 3T3-L1 cells
Our previous results strongly suggest that signals from immune cells (most likely ATMs)
to adipocytes are capable of reducing lipid accumulation in pWAT in mice reconstituted with LXRa S196A compared to WT ( Fig. 5C-E) . To test this, we developed an in vitro assay whereby 3T3-L1 cells are differentiated into adipocytes, treated for 24 hours with filtered conditioned media (CM) from either LXRa WT or S196A BMDMs under different inflammatory states (M0, M1 or M2), and stained for neutral lipids by Oil Red O (ORO) to determine lipid accumulation ( Fig. 7A ).
We found that conditioned media from M1 WT BMDMs promoted more lipid accumulation in adipocytes than conditioned media from M1 S196A BMDMs, whereas conditioned media from M0 and M2 from either WT or S196A BMDMs showed no differences in lipid accumulation ( Fig.   7B ). This suggests M1 S196A cells secrete differing factors than M1 WT macrophages; a decrease in pro-inflammatory and/or an increase in anti-inflammatory factors, that promotes lipid accumulation.
We therefore compared the level of cytokines in the media of M1 LXRa WT and S196A
BMDMs using a cytokine array. We found in S196A relative to WT conditioned media a significant decrease in the pro-inflammatory cytokines IL1β, IL27 and CXCL2, as well as an increase in CCL3, CXCL9, and CD54 (Fig. 8C ). The anti-inflammatory cytokine IL4, CCL1, and IL13 were increased in S196A conditioned media compared to WT BMDMs (Fig. 8C ). We also found the mRNA expression of IL1β was lower in S196A versus WT BMDMs by RNA-seq (not shown). Our findings suggest that LXRa S196A M1 macrophages suppress lipid accumulation in adipocytes by reducing and/or enhancing the levels of pro-inflammatory and anti-inflammatory cytokines.
DISCUSSION
We examined the effects of LXRa pS196 on atherosclerosis progression and obesity within the same mouse by expressing LXRa S196A in all myeloid cells in a bone marrow transplant model in Ldlr -/recipients. We found that expression of LXRa S196A increased HDL-C and reduced LDL-C levels. The increase in HDL-C is possibly through recruitment to the liver of LXRa S196A expressing resident macrophages (Kupffer cells) in the context of bone marrow transplantation after whole body irradiation to influence liver cells to either increase HDL-C particle secretion or decrease HDL-C uptake (52) (53) (54) . Consistent with an increase in HDL-C in LXRa S196A, we observed a decrease in neutral lipid accumulation in plaque macrophages expressing S196A. We also found that expression of LXRa S196A reduced the recruitment of inflammation-prone Ly6C high monocytes, which in turn would reduce these monocytes becoming macrophages, and local macrophage proliferation, thus blunting atherosclerotic plaque formation, although this reduction was opposed by decreased macrophage apoptosis.
We also observed from the CD68+ cells laser captured from the plaque of LXRa S196A mice an anti-inflammatory gene expression signature associated with the upregulation of genes involved in oxidative phosphorylation, and mitochondrial activity ( Fig. 3B ). PGC1a, a transcriptional coactivator that coordinates mitochondrial biogenesis (28, 29, 55) and a LXRa coactivator (27) , was the top putative transcriptional regulator in plaque CD68+ cells expressing LXRa S196A. PCG1 is activated by deacetylation via sirutins (30) , and one of the top IPA pathways induced by LXRa S196A in CD68+ cells is sirutin signaling. This suggests that the nonphosphorylated form of LXRa at S196 may help activate PGC1 via deacetylation and preferentially utilize PGC1a as a coactivator in this context. In fact, the amount of transcriptional coactivation by PGC1a of LXRa in cultured cells was greater when cells were treated with both LXR and RXR ligands (27) , which we reported reduced LXRa S196 phosphorylation and induced
LXRa non-phosphorylation-dependent target gene expression compared to treatment with either ligand alone (56).
Consistent with changes in genes linked to mitochondrial activity, we demonstrated in S196A BMDMs polarized in vitro to the M1 or M2 states, upregulation of basal respiration, ATP production ( Fig. 4A ), and increased mitochondrial abundance ( Fig. 4B-C) , and mitochondria morphology reminiscent of M2 BMDMs (Fig 4D) . This indicates that both subsets of S196A macrophages utilize fatty acid metabolism to a greater extent than their WT counterparts. Since the rewiring of macrophage metabolism from glycolytic to oxidative phosphorylation is a hallmark of the anti-inflammatory response by M2 macrophages, our findings suggest that S196A expression in CD68+ cells in the plaque promotes the acquisition of the characteristics of antiinflammatory macrophages (25).
Surprisingly, we also found that expression of LXRa S196A in the bone marrow significantly reduced mouse weight, total fat, pWAT, and adipocyte size in pWAT compared to WT ( Fig. 5 ). This phenotype was not reported in macrophage-specific S196A expressing mice in the Ldlr -/background (17), suggesting that other bone marrow-derived cells in combination with macrophages are promoting this phenotype. The decrease in adipocyte size in LXRa S196A was associated with reduced numbers of pro-inflammatory ATMs in the adipose tissue ( Fig. 6A-E) , and a large change in the LXRa S196A transcriptomes between ATM subtypes that indicated a less inflammatory phenotype. We did not observe any expression of UCP1 in the pWAT by qPCR or IHC (not shown), suggesting the effect of LXRa S196A from bone marrow-derived cells on pWAT was not a result of conversion into beige fat via UCP1 (57) . Rather, we suggest the reduction in adipocyte size is a result of a decline in pro-inflammatory ATM infiltration and a decrease in the secretion of inflammatory factors (and/or an increase in the secretion of antiinflammatory molecules) from LXRa S196A compared WT ATMs.
As noted above, our studies indicated that LXRa S196A promoted an anti-inflammatory phenotype within the ATMs of adipose tissue. Previous studies demonstrated that reconstitution of wild type mice with LXRa/β knock-out bone marrow, which would be predicted to exacerbate obesity due to a reduction in the LXRs anti-inflammatory response, had no effect on diet-induced obesity (58) . However, in ob/ob mice that were LXRa/β deficient, there was enhanced inflammation and increased macrophage content in adipose tissue, although the mice did not become more obese (59) . Thus, it appears that depending on the physiological context, the effects of LXRs in general, and LXRa pS196 in particular, on inflammation and obesity vary. It will be interesting to see whether expression of LXRa S196A in the bone marrow of ob/ob mice would ameliorate obesity, or whether the effect on obesity of LXRa S196A in other genetic backgrounds would be the same, since Ldlr -/compared to Apoe -/mice are more prone to diet-induced obesity (60, 61) through pathways affecting leptin and AMPK (62) .
Given that LXRa S196A in our bone marrow transplant model is expressed only in myeloid cells and not in the adipocytes, we hypothesized that in the S196A mice, factors secreted by ATMs in WT are reduced in their abundance if pro-inflammatory, or increased in their levels if anti-inflammatory, which could drive the lipid accumulation in adipocytes. In fact, incubation of 3T3-L1 with conditioned media from M1 LXRa S196A BMDMs showed reduced neutral lipid staining compared to M1 LXRa WT BMDM conditioned media, consistent with LXRa S196A
BMDMs having reduced levels of pro-inflammatory (and/or increased levels of antiinflammatory) secreted factors (Fig. 7B ). The myeloid specific expression of LXRa S196A was not reported to reduce obesity in the Ldlr -/background (17), yet conditioned media from LXRa S196A M1 BMDM compared to WT suppressed lipid accumulation in adipocytes in culture. This suggests differences in the abundance and/or activity of inflammatory mediators secreted by LXRa S196A M1 BMDMs in vitro or LXRa S196A when expressed in the bone marrow transplant model relative to the myeloid-specific LXRa S196A expression in vivo.
It has been previously demonstrated that LXRa inhibits the transcription of proinflammatory cytokines, such as IL1β, IL6, IL18 and TNFa (63, 64) , although the effect of LXRa S196A on transrepression of genes expressing inflammatory factors remains unclear. In principle, LXRa S196A could increase transrepression, thus further inhibiting expression of proinflammatory targets (65) . We demonstrated that multiple cytokines were differentially secreted by the inhibition of LXRa pS196, including a decrease in the pro-inflammatory cytokines IL1β, and an increase in the anti-inflammatory factor IL4 and IL13 (Fig. 7C) . Given that IL4 and IL13 promote M2 polarization (65) , this suggests that LXRa S196A cells could more readily assume M2-like characteristics relative to WT cells. Indeed, the metabolic alterations observed in S196A macrophages (e.g., upregulation of oxidative phosphorylation and mitochondrial biogenesis) are consistent with a more pronounced anti-inflammatory M2 phenotype (65) . IL1β is also an attractive candidate since it is a pro-inflammatory factor downregulated in LXRa S196A compared to WT M1 conditioned media. A clinical trial (CANTOS) has demonstrated a reduction in atherosclerosis using a therapeutic monoclonal antibody targeting IL1β (66) . IL1β is also an established factor involved in macrophage-adipocyte crosstalk and can promote the development of obesity (67) . Furthermore, IL1β mRNA expression was reduced in LXRa S196A versus WT BMDMs by RNA-seq (not shown). Further experiments using neutralizing antibodies or genetic deletions will be required to define the factor(s) released by macrophages responsible for reduced lipid accumulation in adipocytes by macrophages expressing S196A.
Our findings complement a recent elegant study by Gage et al. that demonstrated a myeloid-specific knock-in of LXRa S196A resulted in greater macrophage proliferation via the LXRa S196A dependent upregulation of FOXM1, and increased atherosclerosis (17) . The difference in the phenotypes between the myeloid-specific expression of S196A versus our bone marrow transplant model, in which the entire complement of hematopoietic cells express LXRa S196A suggest that LXRa S196A expression within additional bone marrow-derived cells restrain In summary, we showed that reducing LXRa pS196 in bone marrow cells of Ldlr -/mice reduced VAT weight and attenuated atherosclerosis. This was accompanied by a shift in macrophages to a less inflammatory state in LXRa S196A compared to WT in both tissue microenvironments through reprograming of LXRa-dependent transcription. However, the specific genes that change in expression were largely non-overlapping between plaques and VAT macrophages (TableS4). This is similar to recent single-cell RNA sequencing of macrophages from plaques and adipose tissue in western diet fed mice (8, 12) .
Reducing LXRa pS196 in the bone marrow results in favorable effects on macrophage metabolism that are beneficial in reducing atherosclerosis and obesity. This is reminiscent of the effects of exercise on reducing macrophage inflammation (69, 70) . We speculate that exercise 
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MATERIALS AND CORRESPODANCE
MATERIALS AND METHODS
Animals
C57BL/6 LXRa S196A mice were generated by Ozgene, and have been described (17, 19 sucrose/saline. Organs weight was measured. Aortic roots were dissected and embedded in optimal cutting temperature (OCT) compound medium and frozen immediately, and stored at -80°C until further use. pWAT was collected and digested for immune cells analysis, and adipocytes were collected in Trizol (Invitrogen). Liver, pWAT and BAT were fixed in formalin and then embedded in paraffin for further IHC studies. The data presented are from male mice to focus on a single experimental cohort with similar body size and hormonal milieu.
Mouse genotyping
Genotyping was performed by mouse tail DNA PCR analysis. Genotyping was performed using the following PCR primers: R2: 5′-AAGCATGACCTGCACACAAG-3′; WT: 5′-GGTGTCCCCAAGGGTGTCCT-3′; and SA: 5′-GGTGTCCCCAAGGGTGTCCG-3′. Primers R2 and WT identify the wild-type allele (642-bp) and primers R2 and SA identify mutant allele of LXRa S196A global knock-in mice (656-bp).
Blood adiponectin and plasma lipoprotein measures
Blood samples were centrifuged at 10,000 rpm for 10 minutes and the supernatants collected as plasma. Plasma adiponectin concentration was quantified using the adiponectin mouse ELISA kit (Thermo Fisher Scientific). Total cholesterol, triglyceride, non-esterified fatty acid and HDL-C concentrations in plasma were measured using colorimetric assays (Wako Diagnostics). For plasma lipoprotein analysis: for each group, equal volume of plasma per mice were pooled.
Lipoproteins were separated by fast-performance liquid chromatography (Superose 6 10/300 GL column, GE Healthcare, PA, USA) on a Shimadzu HPLC system. Following separation, fractions were collected and cholesterol content was quantified by colorimetric assays.
Body fat composition
We assessed the total fat mass, lean mass, and bone mineral density (BMD) of mice after 10 weeks of western diet feeding using the LUNAR PIXIMUS bone densitometer (Lunar Corp.). Mice were anesthetized by continuous-inhalation of isoflurane and placed in a prone position on the detector tray to scan the entire mouse body. This non-invasive technique provides quantitative data on the fat tissue content, the lean tissue content, and BMD.
Histochemical analyses
To measure lesions in the aortic root, the heart and proximal aorta were excised and the apex and lower half of the ventricles were removed. Tissues were sectioned at 6µm intervals using a cryostat (for frozen blocks) or a microtome (for paraffin blocks). For frozen tissue sections, slides were fixed in acetone for 10 minutes at -20 °C. For paraffin sections, slides were dewaxed in xylene, rehydrated and boiled for 20 minutes in citrate buffer (10mM, pH 6.0) for antigen retrieval. After 
Immunofluorescence on tissues
Hematology parameters by flow cytometry
Blood was collected before sacrificing the mice by tail bleeding. Total white blood cells (WBCs)
were determined using the Genesis Hematology System (Oxford Science, Oxford, CT). Red blood cells were lysed with red blood cells lysis buffer (Sigma-Aldrich) and cells were stained with Percp/Cy5.5 anti-mouse CD45, PE anti-mouse CD115, and APC anti-mouse Ly6C/6G (Biolegend). Monocytes and neutrophils were identified by flow cytometry using a LSRII analyzer and analyzed using FlowJo v10.
Laser capture microdissection and RNA-seq analysis 6 µm sections of aortic roots were collected on Pen membrane Frame Slides (Arcturus). CD68+ cells were isolated from atherosclerotic plaques by laser capture microdissection performed under RNase-free conditions (71, 72) . Aortic root sections were stained with hematoxylin-eosin and cells were captured from approximately 36 frozen sections. After laser capture microdissection, RNA was isolated using the PicoPure RNA isolation kit (Thermo Fisher scientific), and quality and quantity were determined using an Agilent 2100 Bioanalyzer (Agilent Technologies). RNA-seq libraries were prepared using the Clontech SMARTer Stranded Total RNA-Seq Kit -Pico Input
Mammalian following the manufacturer's protocol. Libraries were purified using AMPure beads, pooled equimolarly, and run on a HiSeq 2500, paired end reads. FASTQ files were obtained and STAR 2.5 was used for read mapping against the mm10 reference genome. BAM alignment files were processed using Featurecounts 1.0.5. DESeq2 (3.4) was used to identify differentially expressed genes (DEG). Genes with a p-value < 0.05 were determined to be differentially expressed (Fold change >1.5) and the Ingenuity Pathway Analysis (Qiagen) was used for pathway and transcription factor analysis.
Bone marrow derived macrophages cell culture
Bone marrow cells were isolated by flushing cells from the femurs and tibiae of mice. Cells were differentiated into bone marrow derived macrophages (BMDMs) in 4.5 g/L glucose DMEM (Lonza) with 20% fetal bovine serum (FBS), 1% penicillin/streptomycin, and murine M-CSF (10 ng/mL; PeproTech) at 37 °C and 5% CO 2 for 7 days. The BMDMs were treated with LPS (10ng /mL, Sigma-Aldrich) and murine IFNγ (20 ng/mL, BD Biosciences) for M1 polarization, with murine IL4 (15 ng/mL; BD Biosciences) for M2 polarization or without treatment for control M0, for 24 hours.
Mitochondrial activity: Seahorse assay
Oxygen consumption was measured in a Seahorse XF24 Analyzer (Agilent). Differentiated
BMDMs were seeded at 0.25x10 6 cells/well in XF24-well plates (Agilent) and polarized for M0, M1, and M2 for 24 hr, as described above. Wells without cells were included as a background control. Sensor plates were calibrated overnight in a CO 2 -free incubator at 37°C using 1 mL/well of XF calibrant solution (Agilent). After polarization, culture medium was replaced with glucosefree DMEM (Agilent) medium supplemented with 2 µM L-glutamine, 1 µM pyruvate and 10 mM glucose (Agilent) and cells were incubated 1 hr in a CO 2 -free incubator at 37°C. Injection ports were loaded with 10X injection mixes to obtain a final concentration in each well of 20 mM glucose after the first injection, 1.5 µM oligomycin after the second injection, 1.5 µM FCCP after the third injection, and 0.5 µM rotenone plus 0.5 µM antimycin A after the fourth injection. After the run, supernatants were carefully aspirated and cells were fixed with methanol and stained for DAPI (Invitrogen). Cells were imaged and counted using the CellInsight CX7 LZR High Content Analysis Platform (Thermo Fisher Scientific). OCR values were normalized to cell number for each well.
Determination of mitochondrial abundance: MitoTracker
BMDMs were seeded at 1x10 5 cells/well in 8 wells Nunc Lab-Tek II Chamber Slide (Thermo Scientific). The next day, cells were polarized for M0, M1, and M2 as described above. After 24 hours, cells were treated with 100 nM MitoTracker Red CMXRos for 30 minutes at 37°C, fixed in methanol and stained for DAPI (Invitrogen). Images were taken using an EVOS m7000 Imaging System.
Determination of mitochondrial abundance: mitochondrial DNA measure
BMDMs were seeded at 0.6x10 6 cells/mL in 12-well plates and differentiated as described above.
The next day, total DNA was extracted from BMDMs using a DNeasy Blood & Tissue Kit 
3T3-L1 cell culture and differentiation
3T3-L1 cells were cultured in 4.5 g/L glucose DMEM (Lonza) with 10% FBS, 1% penicillin/streptomycin (complete DMEM) at 37 °C and 5% CO 2 . 3T3-L1 preadipocytes were induced to differentiate by incubation with differentiation medium containing 0.5 mM IBMX (Sigma-Aldrich), 1 µg/mL insulin (Gibco), 0.25 µM dexamethasone (Sigma-Aldrich) and 2 µM rosiglitazone (Cayman Chemical Company) in complete DMEM for 2 days. The cells were then incubated with complete media containing 10 µg/mL insulin for 3 days. Then conditioned media from M0, M1, or M2
BMDMs was filtered and added to the differentiated 3T3-L1 for 24 hours. Lipid accumulation was observed by staining with Oil Red O (ORO) staining: cells were fixed with 4% formaldehyde for 15 minutes, incubated with 60% isopropanol (Fisher Chemical) for 5 minutes, stained with 0.3% Oil Red O (Sigma-Aldrich) in 60% isopropanol for 30 minutes at room temperature and counterstained with hematoxylin (Vector Laboratories). Images were taken using the EVOS FL COLOR imaging system.
Determination of secreted cytokines
Cytokine levels in cell culture supernatants samples were determined using the Proteome Profiler Mouse Cytokine Array Panel A (R&D Systems) following the manufacturer recommendations.
Separation of Stromal Vascular Cells (SVC)
Isolation was performed as described by Weisberg et al (73) . Perigonadal fat pads were minced, placed in DMEM supplemented with 10 mg/ml fatty acid-poor BSA, and centrifuged at 1000 × g for 10 minutes. A LPS-depleted collagenase mixture (Liberase TM , Roche Applied Science) at a concentration of 0.03 mg/ml and 50 units/ml DNase I (Sigma) was added to the tissue, and the samples were incubated at 37 °C in a rotating shaker for 45 minutes. Then, the samples were passed through a 70-µm nylon cell strainer (Corning). The suspension was centrifuged at 1000 × g for 10 minutes, and the pelleted cells were collected as the SVC. The floating cells were collected as the adipocytes. The SVC were resuspended in red blood cells lysis buffer (Sigma-Aldrich) and incubated at room temperature for 5 minutes and washed in PBS.
RT-qPCR of adipocytes
Total RNA was extracted from adipocytes with TRIzol (Invitrogen) and was reverse transcribed Magnification at 19,500X and 31,000X is shown. Data are expressed as mean ± SD (n=3). T test; *P<0.05, **P<0.01 and ***P<0.001. Representative images of hematoxylin and eosin stained pWAT from LXRα WT and S196A mice.
(E) Quantification of the frequency of adipocytes at indicated size ranges and adipocyte size in LXRα WT and S196A mice. Scale bars: 400µm. Data are expressed as mean ± SD (n=14 per group). T test; *P<0.05 and **P<0.01. Supplementary Table 1 : Genes differentially expressed in LXRα S196A versus WT from plaque CD68+ cells Supplementary Table 2 : Genes within IPA pathways in LXRα S196A versus WT from plaque CD68+ cells Supplementary Table 3 : Genes differentially expressed in ATMs from LXR WT and S196A Supplementary Table 4 : Genes within IPA pathways unique to LXRαWT and S196A in ATMs Genes regulated by LXR S196A 
Supplementary Table 5: Genes common between plaque CD68+ cells and ATMs
